Avecho Biotechnology Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Avecho Biotechnology's earnings have been declining at an average annual rate of -26.6%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 43.3% per year.
Anahtar bilgiler
-26.6%
Kazanç büyüme oranı
-19.4%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 31.2% |
Gelir büyüme oranı | -43.3% |
Özkaynak getirisi | -82.6% |
Net Marj | -1,026.9% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth
Jan 13Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation
May 31Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely
Jul 14We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth
Mar 23We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate
Dec 08Gelir ve Gider Dağılımı
Avecho Biotechnology nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 0 | -3 | 2 | 1 |
31 Mar 24 | 0 | -3 | 2 | 1 |
31 Dec 23 | 0 | -3 | 2 | 1 |
30 Sep 23 | 1 | -4 | 3 | 1 |
30 Jun 23 | 1 | -4 | 3 | 1 |
31 Mar 23 | 1 | -3 | 3 | 1 |
31 Dec 22 | 1 | -2 | 2 | 1 |
30 Sep 22 | 1 | -2 | 2 | 1 |
30 Jun 22 | 1 | -2 | 3 | 1 |
31 Mar 22 | 1 | -3 | 3 | 1 |
31 Dec 21 | 1 | -3 | 3 | 1 |
30 Sep 21 | 1 | -3 | 3 | 1 |
30 Jun 21 | 0 | -3 | 3 | 1 |
31 Mar 21 | 0 | -3 | 3 | 0 |
31 Dec 20 | 0 | -3 | 3 | 0 |
30 Sep 20 | 0 | -2 | 2 | 0 |
30 Jun 20 | 0 | -2 | 2 | 0 |
31 Mar 20 | 2 | -1 | 2 | 0 |
31 Dec 19 | 4 | 1 | 2 | 0 |
30 Sep 19 | 4 | 1 | 2 | 0 |
30 Jun 19 | 5 | 0 | 3 | 0 |
31 Mar 19 | 3 | -2 | 3 | 0 |
31 Dec 18 | 1 | -4 | 4 | 0 |
30 Jun 18 | 1 | -6 | 6 | 1 |
31 Mar 18 | 1 | -7 | 7 | 1 |
31 Dec 17 | 1 | -9 | 8 | 1 |
30 Jun 17 | 1 | -16 | 8 | 1 |
31 Mar 17 | 1 | -17 | 8 | 1 |
31 Dec 16 | 2 | -17 | 8 | 2 |
30 Sep 16 | 2 | -17 | 9 | 2 |
30 Jun 16 | 3 | -17 | 9 | 2 |
31 Mar 16 | 2 | -18 | 9 | 2 |
31 Dec 15 | 2 | -20 | 9 | 2 |
30 Sep 15 | 2 | -17 | 8 | 2 |
30 Jun 15 | 3 | -14 | 7 | 3 |
31 Mar 15 | 2 | -10 | 6 | 3 |
31 Dec 14 | 2 | -7 | 6 | 3 |
30 Jun 14 | 1 | -7 | 6 | 3 |
31 Mar 14 | 1 | -9 | 7 | 3 |
31 Dec 13 | 1 | -11 | 7 | 4 |
Kaliteli Kazançlar: AVE is currently unprofitable.
Büyüyen Kar Marjı: AVE is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: AVE is unprofitable, and losses have increased over the past 5 years at a rate of 26.6% per year.
Büyüme Hızlandırma: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Özkaynak Getirisi
Yüksek ROE: AVE has a negative Return on Equity (-82.63%), as it is currently unprofitable.